Perceptive closes life sciences VC fund at $515m

Perceptive Advisors has noticed an uptick of investor interest in the life sciences sector as it held the final close for its latest venture capital fund at $515 million.

The Perceptive Xontogeny Venture Fund II was oversubscribed and furthers the New York-based group’s early-stage life sciences platform. The close of PXV Fund II triples the assets under management to $725 million in less than two years of the closing of the inaugural fund.

The fund’s strategy complements Perceptive Advisors’ Life Sciences hedge fund and credit opportunities funds in that it will . . .

Continue Reading

Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Annual subscriptions get you the most bang for your buck, including access to Alternatives Watch Research articles and out Annual Investor Compendium.

Monthly subscriptions and discounted corporate plans for up to 100 members also available.

Related Articles

Back to top button

Start Your Days in the Know


Get fresh alts intel in your inbox with our FREE newsletter!

You have Successfully Subscribed!